News & Events

Clinical Trials Latest News

Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval

Enrolment completed - 120 patients with end-stage renal disease in 22 centers in Europe Primary endpoint readouts anticipated in Q2…

adminJanuary 7, 2025

Clinical Trials Latest News

Xeltis announces FDA Breakthrough Device Designation for aXess™ and first patient treated in US pivotal trial

Designation recognizes aXess has the potential of providing a more effective vascular access option for dialysis patients, bringing significant advantages…

adminNovember 14, 2024

Latest News

Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development

Brings over 30 years of experience in cardiovascular clinical research, business development, training, education, and medical affairs Strengthens Xeltis’ leadership…

adminNovember 5, 2024

Latest News

Xeltis appoints Shawn Gage as Vice President of US Clinical Affairs

Brings extensive experience in design, development, and implementation of US medtech clinical trial strategy for hemodialysis and vascular access Follows…

adminJuly 23, 2024

Clinical Trials Latest News

Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXess™, its restorative vascular access conduit

aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, permanent,…

adminJune 13, 2024

Events Latest News

Xeltis Announces Latest Results from aXess™ Trials to be Presented at 46th Annual Charing Cross Symposium

Two key presentations by leading KOLs highlight positive results from aXess trials in adult patients with end-stage renal disease who…

adminApril 17, 2024

Publications

Exceptional 6-month data from Xeltis’ FIH aXess vascular conduit trial published in Journal of Vascular Access

The exceptional six-month data from Xeltis’ first-in-human (FIH) aXess conduit trial has been published in the Journal of Vascular Access.…

Content TeamFebruary 8, 2024

Clinical Trials Events Latest News

Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023

aXess demonstrated exceptional patency rates and no infections to date Xeltis, a leading developer of transformative implants that enable the…

Content TeamNovember 17, 2023

Latest News

Xeltis appoints Luciën van Os as Chief Operating Officer

Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces the…

Content TeamSeptember 12, 2023

Latest News

Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing

Funding extends Xeltis’ Series D2 financing round to €44.5 million. Xeltis a leading developer of transformative implants that enable the…

Content TeamAugust 15, 2023

Latest News

XABG unprecedented preclinical outcomes for a CABG device may outperform saphenous veins

Preclinical data on Xeltis restorative Coronary Artery Bypass Graft (CABG) device, XABG, show unprecedented one-year patency for a CABG device,…

Content TeamJune 19, 2023

Clinical Trials

Xeltis’ aXess implanted in first patient in Poland

Xeltis’ restorative vascular access graft, aXess, has been successfully implanted in the first patient in Poland, as part of the…

Content TeamJune 19, 2023

Clinical Trials

Xeltis’ aXess implanted in first patient in Greece

aXess, Xeltis’ restorative vascular access graft for hemodialysis, has been successfully implanted in the first patient in Greece, as part…

Content TeamMay 17, 2023

Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress

aXess graft demonstrated excellent patency, low rates of infection and re-intervention Data indicates a significant improvement in performance compared to…

Content TeamApril 28, 2023

Finances

Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices

New investors DaVita Venture Group and Invest-NL join syndicate of international investors, including Grand Pharma and EQT Life Sciences, investing…

Content TeamFebruary 21, 2023

Clinical Trials

Xeltis materials confirm outstanding restorative properties

The Xeltis materials have been showing outstanding restorative outcomes in preclinical trials presented by Dr Madeline Cramer, University of Pittsburgh,…

Content TeamNovember 30, 2022

Events

Professor Moll presents aXess at VEITH

Professor Frans Moll, University Medical Center Utrecht, will update an audience of international vascular surgeons at the VEITH Symposium in…

Content TeamNovember 18, 2022

Clinical Trials

Dr An De Vriese discusses the AXESS Pivotal trial in Renal Interventions

Dr An de Vriese, who is playing a leading role in the ongoing European pivotal trial investigating the aXess vascular…

Content TeamNovember 17, 2022

Clinical Trials

Xeltis starts the pivotal clinical trial for aXess

Xeltis has started the pivotal trial for the first-ever restorative synthetic hemodialysis access grafts, aXess. The first two patients have…

Content TeamNovember 10, 2022

Clinical Trials

XABG unprecedented preclinical outcomes for a CABG device may outperform saphenous veins

Preclinical data on Xeltis restorative Coronary Artery Bypass Graft (CABG) device, XABG, show unprecedented one-year patency for a CABG device,…

Content TeamNovember 9, 2022

Finances

Xeltis receives commitment from Grand Pharma to invest €15M

The Chinese company Grand Pharmaceutical Group Ltd (0512.HK) has committed to invest €15 million in equity and license fees, as…

Content TeamAugust 9, 2022

Publications

Pivotal Study protocol publication for aXess hemodialysis graft

The protocol for our ongoing Pivotal Study for the aXess hemodialysis graft has been published in the Journal of Vascular…

Content TeamMay 30, 2022

Publications

Novel in vivo imaging of Xeltis devices advances understanding of ETR – in Frontiers

Results from novel imaging analysis of the Endogenous Tissue Restoration (ETR) process in Xeltis’ devices further advance the understanding of…

Content TeamMay 3, 2022

Featured

aXess and new directions for vascular access grafts

Renal Interventions dedicated a feature article to arteriovenous grafts (AVG) for hemodialysis access, in which Xeltis’ restorative AVG graft aXess…

Content TeamApril 8, 2022

Publications

Xeltis pioneers supramolecular materials for cardiovascular restoration in patients

Xeltis’ devices are the first living applications of supramolecular materials for cardiovascular restoration in patients. An article published in peer-reviewed…

Content TeamApril 5, 2022

Clinical Trials

XABG preclinical trial showed superior performance vs harvested veins at one year

Results from preclinical trials of Xeltis restorative coronary artery bypass graft XABG showed superior performance of the Xeltis graft compared…

Content TeamMarch 11, 2022

Featured

Vascular experts discuss aXess in dialysis patients

Matteo Tozzi, MD, vascular surgeon and professor of vascular surgery at Università dell’Insubria in Italy, and Frans L. Moll, MD,…

Content TeamJanuary 12, 2022

Finances

Xeltis receives €15M funding from EIC Accelerator

Xeltis will receive €15 million in funding from the European Innovation Council Accelerator (EIC) set up by the European Commission.…

Content TeamDecember 21, 2021

Finances

Xeltis lands €15 million European financing from EIB

The European Investment Bank (EIB) has signed a €15 million quasi-equity financing agreement with Xeltis. The EIB’s non-dilutive financing will…

Content TeamNovember 22, 2021

Publications

ETR Insights from Xeltis restorative pulmonary valve in Acta Biomaterialia

The latest insights on the fascinating mechanisms behind endogenous tissue restoration (ETR), the process that transforms Xeltis devices into living…

adminOctober 14, 2021

Featured

aXess and new directions for vascular access grafts

Renal Interventions dedicated a feature article to arteriovenous grafts (AVG) for hemodialysis access, in which Xeltis’ restorative AVG graft aXess…

Content TeamApril 8, 2022

Featured

Vascular experts discuss aXess in dialysis patients

Matteo Tozzi, MD, vascular surgeon and professor of vascular surgery at Università dell’Insubria in Italy, and Frans L. Moll, MD,…

Content TeamJanuary 12, 2022

Events Latest News

Xeltis Announces Latest Results from aXess™ Trials to be Presented at 46th Annual Charing Cross Symposium

Two key presentations by leading KOLs highlight positive results from aXess trials in adult patients with end-stage renal disease who…

adminApril 17, 2024

Clinical Trials Events Latest News

Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023

aXess demonstrated exceptional patency rates and no infections to date Xeltis, a leading developer of transformative implants that enable the…

Content TeamNovember 17, 2023

Events

Professor Moll presents aXess at VEITH

Professor Frans Moll, University Medical Center Utrecht, will update an audience of international vascular surgeons at the VEITH Symposium in…

Content TeamNovember 18, 2022

Events

Xeltis living heart valves to epitomize innovative medtech at the Spirit of Bern

Xeltis has been selected with three other Swiss companies to illustrate how medtech innovation can pave new ways to improve…

adminFebruary 25, 2021

Publications

Exceptional 6-month data from Xeltis’ FIH aXess vascular conduit trial published in Journal of Vascular Access

The exceptional six-month data from Xeltis’ first-in-human (FIH) aXess conduit trial has been published in the Journal of Vascular Access.…

Content TeamFebruary 8, 2024

Publications

Pivotal Study protocol publication for aXess hemodialysis graft

The protocol for our ongoing Pivotal Study for the aXess hemodialysis graft has been published in the Journal of Vascular…

Content TeamMay 30, 2022

Publications

Novel in vivo imaging of Xeltis devices advances understanding of ETR – in Frontiers

Results from novel imaging analysis of the Endogenous Tissue Restoration (ETR) process in Xeltis’ devices further advance the understanding of…

Content TeamMay 3, 2022

Publications

Xeltis pioneers supramolecular materials for cardiovascular restoration in patients

Xeltis’ devices are the first living applications of supramolecular materials for cardiovascular restoration in patients. An article published in peer-reviewed…

Content TeamApril 5, 2022

Publications

ETR Insights from Xeltis restorative pulmonary valve in Acta Biomaterialia

The latest insights on the fascinating mechanisms behind endogenous tissue restoration (ETR), the process that transforms Xeltis devices into living…

adminOctober 14, 2021

Publications

Superior biocompatibility of Xeltis materials vs conventional heart valve devices published in JBMR

Xeltis’ polymers have shown superior pro-healing response and no calcification compared to conventional biological heart valve devices in preclinical trial…

adminAugust 6, 2021

Publications

Excellent performance and safety data on Xeltis bio-restorative technology published

Promising early outcomes from two clinical trials of Xeltis pulmonary valve confirm the excellent safety and performance of its bio-restorative…

adminMarch 12, 2021

Publications

Xeltis’ RestoreX™ in Cardiovascular Pathology

Peer-reviewed journal Cardiovascular Pathology published positive one-year in-vivo data on Xeltis’ RestoreX™ technology platform in its latest issue. According to…

adminMarch 8, 2019

Finances

Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices

New investors DaVita Venture Group and Invest-NL join syndicate of international investors, including Grand Pharma and EQT Life Sciences, investing…

Content TeamFebruary 21, 2023

Finances

Xeltis receives commitment from Grand Pharma to invest €15M

The Chinese company Grand Pharmaceutical Group Ltd (0512.HK) has committed to invest €15 million in equity and license fees, as…

Content TeamAugust 9, 2022

Finances

Xeltis receives €15M funding from EIC Accelerator

Xeltis will receive €15 million in funding from the European Innovation Council Accelerator (EIC) set up by the European Commission.…

Content TeamDecember 21, 2021

Finances

Xeltis lands €15 million European financing from EIB

The European Investment Bank (EIB) has signed a €15 million quasi-equity financing agreement with Xeltis. The EIB’s non-dilutive financing will…

Content TeamNovember 22, 2021

Finances

Xeltis’ closes €10.5 million Series D financing

Xeltis closed a €10.5 million Series D financing round to support its vascular and valve trial programs this week. The…

adminSeptember 5, 2019

Clinical Trials Latest News

Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval

Enrolment completed - 120 patients with end-stage renal disease in 22 centers in Europe Primary endpoint readouts anticipated in Q2…

adminJanuary 7, 2025

Clinical Trials Latest News

Xeltis announces FDA Breakthrough Device Designation for aXess™ and first patient treated in US pivotal trial

Designation recognizes aXess has the potential of providing a more effective vascular access option for dialysis patients, bringing significant advantages…

adminNovember 14, 2024

Clinical Trials Latest News

Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXess™, its restorative vascular access conduit

aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, permanent,…

adminJune 13, 2024

Clinical Trials Events Latest News

Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023

aXess demonstrated exceptional patency rates and no infections to date Xeltis, a leading developer of transformative implants that enable the…

Content TeamNovember 17, 2023

Clinical Trials

Xeltis’ aXess implanted in first patient in Poland

Xeltis’ restorative vascular access graft, aXess, has been successfully implanted in the first patient in Poland, as part of the…

Content TeamJune 19, 2023

Clinical Trials

Xeltis’ aXess implanted in first patient in Greece

aXess, Xeltis’ restorative vascular access graft for hemodialysis, has been successfully implanted in the first patient in Greece, as part…

Content TeamMay 17, 2023

Clinical Trials

Xeltis materials confirm outstanding restorative properties

The Xeltis materials have been showing outstanding restorative outcomes in preclinical trials presented by Dr Madeline Cramer, University of Pittsburgh,…

Content TeamNovember 30, 2022

Clinical Trials

Dr An De Vriese discusses the AXESS Pivotal trial in Renal Interventions

Dr An de Vriese, who is playing a leading role in the ongoing European pivotal trial investigating the aXess vascular…

Content TeamNovember 17, 2022

Clinical Trials

Xeltis starts the pivotal clinical trial for aXess

Xeltis has started the pivotal trial for the first-ever restorative synthetic hemodialysis access grafts, aXess. The first two patients have…

Content TeamNovember 10, 2022

Clinical Trials

XABG unprecedented preclinical outcomes for a CABG device may outperform saphenous veins

Preclinical data on Xeltis restorative Coronary Artery Bypass Graft (CABG) device, XABG, show unprecedented one-year patency for a CABG device,…

Content TeamNovember 9, 2022

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	CookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	1 year 1 month 4 days	Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.

Keep up to date with all of our latest news and events

LATEST NEWS

Press Releases

Xeltis starts pivotal clinical trial with first ever restorative synthetic hemodialysis access graft

Xeltis presents promising FIH data on restorative hemodialysis access graft at ESVS congress

Xeltis receives commitment from Grand Pharma to invest €15M

Xeltis lands €15 million European financing from EIB

Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve

Media

ETR Powered Platform

Pulmonary Heart Valve

Prof. Mauro Gargiulo

Professor Thierry Carrel

Martijn Cox

Professor Jean-Marie Lehn

A Patient’s Perspective

Global Impact of Heart Valve Disease